Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529628 | 1.00 | TSHR (0.44) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL27770604 | 0.79 | TSHR (0.33) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL27770605 | 0.79 | TSHR (0.33) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL454525 | 0.77 | TSHR (0.44) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL19379407 | 0.77 | TSHR (0.44) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL454524 | 0.77 | TSHR (0.44) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Oxalic Acid SCHEMBL5806860 | 0.74 | TSHR (0.57) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Oxalic Acid SCHEMBL5806857 | 0.74 | TSHR (0.57) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL17856797 | 0.73 | TSHR (0.33) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL351491 | 0.73 | TSHR (0.67) | TSHRTP53EGLN1EGLN3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234434-A | Plant growth promoting system of radiation quantum energy | 云海ENC(株) | 2023-06-06 | — | — | CN | claimed |
| US-8367859-B2 | Cyclohexane 1,4 carboxylates | Amyris, Inc. (US) | 2013-02-05 | — | — | US | claimed |
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250195469-A1 | COMPANION DIAGNOSTICS AND STRATEGIES FOR TREATMENT WITH AN ARYL HYDROCARBON RECEPTOR AGONIST COMPOUND | AZORA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12318413-B2 | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4531860-A1 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | Tes Pharma S.r.l. (IT) | 2025-04-09 | — | — | EP | disclosed |
| EP-4493930-A1 | COMPANION DIAGNOSTICS AND STRATEGIES FOR TREATMENT WITH AN ARYL HYDROCARBON RECEPTOR AGONIST COMPOUND | AZORA THERAPEUTICS, INC. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240058268-A1 | METHODS OF TREATING SKIN DISORDERS | Galderma Holding SA (CH) | 2024-02-22 | — | — | US | disclosed |
| WO-2023227666-A1 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023178288-A1 | COMPANION DIAGNOSTICS AND STRATEGIES FOR TREATMENT WITH AN ARYL HYDROCARBON RECEPTOR AGONIST COMPOUND | AZORA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230233620-A1 | HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES | Kanvas Biosciences, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-4673646-A | Production of 2-hydroxymuconic semialdehyde | CELANESE CORPORATION (US) | 1987-06-16 | — | — | US | disclosed |
| US-4654303-A | Construction of novel mutant microorganisms | CELANESE CORPORATION (US) | 1987-03-31 | — | — | US | disclosed |
| EP-0074169-B1 | MICRO-BIOLOGICAL PRODUCTION OF MUCONIC ACID | CELANESE CORPORATION (US) | 1987-01-14 | — | — | EP | disclosed |
| US-4617156-A | 2-hydroxymuconic semialdehyde bisulfite adduct | CELANESE CORPORATION (US) | 1986-10-14 | — | — | US | disclosed |
| US-4588688-A | Process for the production of muconic acid | CELANESE CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0138391-A1 | Construction of novel mutant micro-organisms | CELGENE CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| EP-0074169-A1 | Micro-biological production of muconic acid | CELANESE CORPORATION (US) | 1983-03-16 | — | — | EP | disclosed |
| EP-0071446-A2 | Construction of microorganisms | CELANESE CORPORATION (US) | 1983-02-09 | — | — | EP | disclosed |
| US-4355107-A | Production of muconic acid | CELANESE CORPORATION (US) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021148-A1 | METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOME | PDCD1, CD274, PDCD1LG2 | TSHR 1153/4885TP53 652/4885EGLN1 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.